Clinical Trials on Floor of Mouth Carcinoma

Total 4489 results

Yonsei University

Active, not recruiting

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment

Korea, Republic of
Hospices Civils de Lyon

Recruiting

Radio/Pathological Evaluation of Tongue Cancer Infiltration (RaP E ToC)

Cell Carcinoma | Oral Squamous

France
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Khon Kaen University

Completed

Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment

Inflammation of Mouth | Acute Mucous Inflammation

Thailand
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

Korea, Republic of, United States, France, Australia, Israel, Spain, United Kingdom, Switzerland
Centre Leon Berard

Completed

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE)

Squamous Cell Carcinoma of the Head and Neck

France
Taizhou Mabtech Pharmaceutical Co.,Ltd

Terminated

Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Squamous Cell Carcinoma of the Head and Neck

China
Iovance Biotherapeutics, Inc.

Completed

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma of the Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Active, not recruiting

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute, Naples

Active, not recruiting

Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (V-CHANCE)

Squamous Cell Carcinoma of the Head and Neck

Italy
Leiden University Medical Center
HollandPTC

Terminated

Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck (ERM-PT-HNSCC)

Squamous Cell Carcinoma of the Head and Neck

Netherlands
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Squamous Cell Carcinoma of the Head and Neck

Spain
Radboud University Medical Center
Erasmus Medical Center; Leiden University Medical Center; Medical Center Haaglanden and other collaborators

Active, not recruiting

A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (COMMENCE)

Squamous Cell Carcinoma of the Head and Neck

Netherlands
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）

Squamous Cell Carcinoma of the Head and Neck

China
Rigshospitalet, Denmark

Completed

Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens (FIGHHT)

Squamous Cell Carcinoma of the Head and Neck

Denmark
Julie E. Bauman, MD, MPH
Novartis

Terminated

Phase II Study of RAD001 Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
AstraZeneca

Completed

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (SUPREME-HN)

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Korea, Republic of, Spain, Greece, Germany, Japan
University of Arkansas

Withdrawn

A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)

Squamous Cell Carcinoma of the Head and Neck

United States
University of Chicago
AstraZeneca

Completed

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States
Merck KGaA, Darmstadt, Germany

Terminated

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

France
University of Tennessee Cancer Institute
National Comprehensive Cancer Network

Terminated

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
University of Arkansas
Erasmus Medical Center; The Netherlands Cancer Institute; Biolitec Pharma Ltd.

Terminated

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck

United States
Sanofi

Completed

Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)

Head and Neck Neoplasms
M.D. Anderson Cancer Center
Pfizer; ISA Pharmaceuticals B.V.

Completed

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Oropharyngeal Cancer | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx

United States
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
Sensei Biotherapeutics, Inc.

Terminated

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
Ezra Cohen
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation

Completed

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (CETLEE011)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Daiichi Sankyo, Inc.

Completed

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
University Hospital Tuebingen

Unknown

Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Sanofi

Completed

Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

France
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Universidade Federal Fluminense

Active, not recruiting

Influence of Surface Sealants on the Quality of Posterior Restorations With Bulk Fill Composites (SEALBULK)

Dental Restoration Failure of Marginal Integrity

Brazil
Universidade Federal Fluminense
Universidade Estadual de Ponta Grossa

Active, not recruiting

Different Application Strategies When Using Futurabond Universal in Class V Cavities (FUUC)

Dental Restoration Failure of Marginal Integrity

Brazil
Universidade Federal Fluminense

Active, not recruiting

Clinical Evaluation of Bulk Fill Composite Restorations Associated to Universal Adhesive System (FBFSBU)

Dental Restoration Failure of Marginal Integrity

Brazil
Universidade Federal Fluminense

Completed

Different Application Strategies When Using Ambar Universal in Class V Cavities (AUC)

Dental Restoration Failure of Marginal Integrity

Brazil
Damascus University

Completed

The Effect of Surgical Interventions to Assist Orthodontic Movement of Impacted Maxillary Canines

Impaction of Tooth

Syrian Arab Republic
Damascus University

Completed

Evaluation of Self-ligating Brackets Plus Minor Surgery in Treating Crowded Cases of Malocclusion

Malocclusion of Anterior Teeth

Syrian Arab Republic
NCIC Clinical Trials Group

Terminated

Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids

Quality of Life | Oral Complications

Canada
Assiut University

Recruiting

Management of Warthin Tumor of Parotid Gland.

Warthin's Tumor of Parotid Gland

Egypt
Alpha Tau Medical LTD.

Recruiting

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Italy
Alpha Tau Medical LTD.

Active, not recruiting

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Israel
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain

Clinical Trials on Floor of Mouth Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations